Acadia Pharmaceuticals Inc (ACAD) 47.56 $ACAD
36.7% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Fri Jul 24, 12:01PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 4 months, Acadia Pharmaceuticals has returned 36.66% as of today's recent price of $49.64.
ACAD: 47.56 (-1.19)
Acadia Pharmaceuticals Has Returned 37.9% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Fri Jul 17, 9:54AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 3 months, Acadia Pharmaceuticals has returned 37.89% as of today's recent price of $50.09.
ACAD: 47.56 (-1.19)
Bellicum appoints Stephen R. Davis to board
M2 - Fri Jul 17, 5:34AM CDT
Biopharmaceutical company Bellicum Pharmaceuticals (Nasdaq:BLCM) disclosed on Thursday the election of Stephen R. Davis to its board of directors, including chairman of the audit committee.
ACAD: 47.56 (-1.19), BLCM: 18.98 (+0.30)
Bellicum Appoints Stephen R. Davis to Board of Directors
Business Wire - Thu Jul 16, 3:05PM CDT
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Stephen R. Davis to its Board of Directors. Mr. Davis was also named Chairman of the Audit Committee.
ACAD: 47.56 (-1.19), BLCM: 18.98 (+0.30)
Critical Alerts For FireEye, Ariad Pharmaceuticals, ACADIA Pharmaceuticals, Esperion Therapeutics and Humana Released By InvestorsObserver
PR Newswire - Wed Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, ARIA, ACAD, ESPR and HUM.
ESPR: 71.65 (-4.26), ACAD: 47.56 (-1.19), FEYE: 46.35 (-0.39), ARIA: 7.67 (-0.03), HUM: 183.91 (+2.15)
Look for Shares of Acadia Pharmaceuticals to Potentially Pullback after Yesterday's 8.71% Rise
Comtex SmarTrend(R) - Tue Jul 14, 4:56PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $44.85 to a high of $49.24. Yesterday, the shares gained 8.7%, which took the trading range above the 3-day high of $45.10 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 47.56 (-1.19)
Uptrend Call Working As Acadia Pharmaceuticals Stock Rises 14.3% (ACAD)
Comtex SmarTrend(R) - Thu Jul 02, 12:13PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 3 months, Acadia Pharmaceuticals has returned 14.33% as of today's recent price of $41.53.
ACAD: 47.56 (-1.19)
Clinical Studies of Disease-Modifying Therapies & Drug Delivery Candidates Lead to New Drug Therapies & Patents for Treating Patients with Parkinson's Disease & Other Neurodegenerative Disorders
PR Newswire - Tue Jun 30, 9:11AM CDT
Over one million Americans suffer from the tremors, stiffness and slurred speech of Parkinson's disease and medications are usually the first-line treatment for this and other neurological conditions. Biopharmaceutical & Biotech companies continue to research through clinical studies to identify diagnostics and develop treatments designed to transform the lives of patients with severe diseases and other rare orphan conditions. Biotech companies in the news are: Amarantus BioScience Holdings, Inc. (OTC:AMBSD), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)
ACAD: 47.56 (-1.19), CPRX: 5.22 (-0.08), ACHN: 8.28 (-0.41), ADMS: 26.15 (-0.65)
ACADIA Pharmaceuticals Is Poised To Outperform The IBB Moving Forward
Brian Nichols - at Seeking Alpha - Mon Jun 22, 2:22PM CDT
ACAD: 47.56 (-1.19), IBB: 373.58 (-4.00)
Seeking Alpha's Biotech Weekly: Bubble Trouble, Allergan's Kythera Takeout, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jun 19, 3:08PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGN: 326.98 (+18.77), ACAD: 47.56 (-1.19), KYTH: 74.35 (+0.18), TKMR: 10.30 (unch), AMGN: 165.54 (+6.95), AERI: 18.55 (-0.07), TEVA: 72.00 (+10.15), LLY: 84.15 (-0.57), PRTA: 62.77 (-1.33), NVS: 101.54 (-0.26), HCC: 77.18 (-0.02)
Acadia Pharmaceuticals Up 11.7% Since SmarTrend Uptrend Call (ACAD)
Comtex SmarTrend(R) - Thu Jun 18, 9:42AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 2 months, Acadia Pharmaceuticals has returned 11.74% as of today's recent price of $40.59.
ACAD: 47.56 (-1.19)
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
Business Wire - Wed Jun 17, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015, at 11:00 a.m. Eastern Time in New York City.
ACAD: 47.56 (-1.19)
Acadia Pharmaceuticals Rises 1.28% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jun 16, 5:36PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $39.47 to a high of $40.81. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.92 on volume of 1.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 47.56 (-1.19)
Acadia Pharma's Nuplazid improves psychosis in Parkinson's patients
Seeking Alpha - at Seeking Alpha - Tue Jun 16, 11:14AM CDT
ACAD: 47.56 (-1.19)
ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID(TM) (Pimavanserin) for Parkinson's Disease Psychosis at the 19th International Congress of Parkinson's Disease and Movement Disorders
Business Wire - Tue Jun 16, 8:00AM CDT
--Data from Two Open-Label Studies Demonstrate Attractive Safety and Tolerability Profile and Potential for Long-Term Effectiveness of NUPLAZID in Parkinson's Disease Psychosis
ACAD: 47.56 (-1.19)
Psychosis - Pipeline Review, H1 2015
M2 - Wed Jun 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkwp5l/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Psychosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned - Acadia Pharmaceuticals - Evotec - Heptares Therapeutics - Newron Pharmaceuticals - Reviva Pharmaceuticals - Sumitomo Dainippon Pharma For more information visit http://www.researchandmarkets.com/research/tkwp5l/psychosis
ACAD: 47.56 (-1.19)
Acadia Pharmaceuticals Falls 4.30% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 09, 5:19PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $38.60 to a high of $40.95. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $40.45 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 47.56 (-1.19)
36.7% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Fri Jul 24, 12:01PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 4 months, Acadia Pharmaceuticals has returned 36.66% as of today's recent price of $49.64.
ACAD: 47.56 (-1.19)
Acadia Pharmaceuticals Has Returned 37.9% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Fri Jul 17, 9:54AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 3 months, Acadia Pharmaceuticals has returned 37.89% as of today's recent price of $50.09.
ACAD: 47.56 (-1.19)
Bellicum appoints Stephen R. Davis to board
M2 - Fri Jul 17, 5:34AM CDT
Biopharmaceutical company Bellicum Pharmaceuticals (Nasdaq:BLCM) disclosed on Thursday the election of Stephen R. Davis to its board of directors, including chairman of the audit committee.
ACAD: 47.56 (-1.19), BLCM: 18.98 (+0.30)
Bellicum Appoints Stephen R. Davis to Board of Directors
Business Wire - Thu Jul 16, 3:05PM CDT
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Stephen R. Davis to its Board of Directors. Mr. Davis was also named Chairman of the Audit Committee.
ACAD: 47.56 (-1.19), BLCM: 18.98 (+0.30)
Critical Alerts For FireEye, Ariad Pharmaceuticals, ACADIA Pharmaceuticals, Esperion Therapeutics and Humana Released By InvestorsObserver
PR Newswire - Wed Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, ARIA, ACAD, ESPR and HUM.
ESPR: 71.65 (-4.26), ACAD: 47.56 (-1.19), FEYE: 46.35 (-0.39), ARIA: 7.67 (-0.03), HUM: 183.91 (+2.15)
Look for Shares of Acadia Pharmaceuticals to Potentially Pullback after Yesterday's 8.71% Rise
Comtex SmarTrend(R) - Tue Jul 14, 4:56PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $44.85 to a high of $49.24. Yesterday, the shares gained 8.7%, which took the trading range above the 3-day high of $45.10 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 47.56 (-1.19)
Uptrend Call Working As Acadia Pharmaceuticals Stock Rises 14.3% (ACAD)
Comtex SmarTrend(R) - Thu Jul 02, 12:13PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 3 months, Acadia Pharmaceuticals has returned 14.33% as of today's recent price of $41.53.
ACAD: 47.56 (-1.19)
Clinical Studies of Disease-Modifying Therapies & Drug Delivery Candidates Lead to New Drug Therapies & Patents for Treating Patients with Parkinson's Disease & Other Neurodegenerative Disorders
PR Newswire - Tue Jun 30, 9:11AM CDT
Over one million Americans suffer from the tremors, stiffness and slurred speech of Parkinson's disease and medications are usually the first-line treatment for this and other neurological conditions. Biopharmaceutical & Biotech companies continue to research through clinical studies to identify diagnostics and develop treatments designed to transform the lives of patients with severe diseases and other rare orphan conditions. Biotech companies in the news are: Amarantus BioScience Holdings, Inc. (OTC:AMBSD), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)
ACAD: 47.56 (-1.19), CPRX: 5.22 (-0.08), ACHN: 8.28 (-0.41), ADMS: 26.15 (-0.65)
ACADIA Pharmaceuticals Is Poised To Outperform The IBB Moving Forward
Brian Nichols - at Seeking Alpha - Mon Jun 22, 2:22PM CDT
ACAD: 47.56 (-1.19), IBB: 373.58 (-4.00)
Seeking Alpha's Biotech Weekly: Bubble Trouble, Allergan's Kythera Takeout, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jun 19, 3:08PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGN: 326.98 (+18.77), ACAD: 47.56 (-1.19), KYTH: 74.35 (+0.18), TKMR: 10.30 (unch), AMGN: 165.54 (+6.95), AERI: 18.55 (-0.07), TEVA: 72.00 (+10.15), LLY: 84.15 (-0.57), PRTA: 62.77 (-1.33), NVS: 101.54 (-0.26), HCC: 77.18 (-0.02)
Acadia Pharmaceuticals Up 11.7% Since SmarTrend Uptrend Call (ACAD)
Comtex SmarTrend(R) - Thu Jun 18, 9:42AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 2 months, Acadia Pharmaceuticals has returned 11.74% as of today's recent price of $40.59.
ACAD: 47.56 (-1.19)
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
Business Wire - Wed Jun 17, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015, at 11:00 a.m. Eastern Time in New York City.
ACAD: 47.56 (-1.19)
Acadia Pharmaceuticals Rises 1.28% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jun 16, 5:36PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $39.47 to a high of $40.81. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.92 on volume of 1.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 47.56 (-1.19)
Acadia Pharma's Nuplazid improves psychosis in Parkinson's patients
Seeking Alpha - at Seeking Alpha - Tue Jun 16, 11:14AM CDT
ACAD: 47.56 (-1.19)
ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID(TM) (Pimavanserin) for Parkinson's Disease Psychosis at the 19th International Congress of Parkinson's Disease and Movement Disorders
Business Wire - Tue Jun 16, 8:00AM CDT
--Data from Two Open-Label Studies Demonstrate Attractive Safety and Tolerability Profile and Potential for Long-Term Effectiveness of NUPLAZID in Parkinson's Disease Psychosis
ACAD: 47.56 (-1.19)
Psychosis - Pipeline Review, H1 2015
M2 - Wed Jun 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkwp5l/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Psychosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned - Acadia Pharmaceuticals - Evotec - Heptares Therapeutics - Newron Pharmaceuticals - Reviva Pharmaceuticals - Sumitomo Dainippon Pharma For more information visit http://www.researchandmarkets.com/research/tkwp5l/psychosis
ACAD: 47.56 (-1.19)
Acadia Pharmaceuticals Falls 4.30% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 09, 5:19PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $38.60 to a high of $40.95. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $40.45 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 47.56 (-1.19)
